Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
- 4 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 44 (1) , 56-66
Abstract
The objective of this study was to analyze the expression and prognostic role of cancer-associated proteins in uterine leiomyosarcoma (uLMS). p53, DAXX, ATRX, HMGA2, IMP3, Stathmin, and phospho-Stathmin (p-Stathmin) protein expression by immunohistochemistry was analyzed in tissue microarrays from 244 uLMS. Expression was assessed for association with clinicopathologic parameters in 173 patients with available data. Tissue microarrays were informative in 230 cases. p53 was aberrant in 44% of tumors. DAXX, ATRX, HMGA2, IMP3, and Stathmin were expressed in 90%, 55%, 40%, 33%, and 97% uLMS, respectively. Cytoplasmic and nuclear p-Stathmin staining was seen in 77% and 68% of tumors, respectively. Stathmin expression was significantly related to higher mitotic count (P < 0.001), a higher degree of atypia (P = 0.006), and vascular invasion (P = 0.016), whereas p-Stathmin expression was significantly related to advanced stage (P < 0.001), higher mitotic count (P < 0.001), and vascular invasion (P = 0.001). In univariate survival analysis for 165 patients with informative tissue microarrays, aberrant p53 (P = 0.026) and higher IMP3 (P = 0.024), Stathmin (P < 0.001), cytoplasmic p-Stathmin (P < 0.001), and nuclear p-Stathmin (P < 0.001) expression was associated with poor disease-specific survival. Clinicopathologic parameters significantly related to poor disease-specific survival were older age (P = 0.006), extrauterine disease at diagnosis (International Federation of Gynecology and Obstetrics (FIGO) stage ≥2; P < 0.001), high mitotic count (P = 0.02), and grade 2 to 3 atypia (P = 0.017). In multivariate analysis, age (P = 0.002), FIGO stage (P < 0.001), and Stathmin expression (P < 0.001) were independent prognosticators. Stathmin was the only prognosticator in a multivariate analysis limited to patients with FIGO stage I disease (P = 0.013). In conclusion, Stathmin expression is strongly associated with poor survival in uLMS and may be a new prognostic marker in this malignancy.Keywords
This publication has 31 references indexed in Scilit:
- Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasCancer, 2021
- Therapeutic strategies to overcome taxane resistance in cancerDrug Resistance Updates, 2021
- Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcomaVirchows Archiv, 2017
- Myxoid leiomyosarcoma of the uterus: a clinicopathological and immunohistochemical study of 10 casesHuman Pathology, 2017
- Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcomaThe Journal of Pathology: Clinical Research, 2015
- Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcomaHuman Pathology, 2012
- Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markersTumor Biology, 2010
- p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpusThe Journal of Pathology, 1995
- p53 protein overexpression in smooth muscle tumors of the uterus*1Human Pathology, 1995
- p53 Alterations in Uterine Leiomyosarcomas versus LeiomyomasGynecologic Oncology, 1994